Stifel Nicolaus Cuts Globus Medical (NYSE:GMED) Price Target to $80.00

Globus Medical (NYSE:GMED) had its target price decreased by research analysts at Stifel Nicolaus from $95.00 to $80.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the medical device company’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 5.73% from the stock’s current price.

GMED has been the subject of several other reports. Needham & Company LLC increased their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Piper Sandler cut their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, June 15th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Royal Bank Of Canada upped their target price on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $106.45.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $75.67 on Wednesday. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40. The firm has a market cap of $10.27 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 1.66 and a beta of 0.95. The stock’s 50-day simple moving average is $81.48 and its 200-day simple moving average is $87.04.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the prior year, the business posted $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts predict that Globus Medical will post 4.74 EPS for the current year.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 18.38% of the stock is currently owned by company insiders.

Institutional Trading of Globus Medical

Several hedge funds have recently made changes to their positions in the stock. Central Pacific Bank Trust Division increased its position in Globus Medical by 20.9% in the second quarter. Central Pacific Bank Trust Division now owns 2,837 shares of the medical device company’s stock worth $224,000 after buying an additional 490 shares during the period. Versant Capital Management Inc increased its holdings in shares of Globus Medical by 67.4% in the 2nd quarter. Versant Capital Management Inc now owns 3,842 shares of the medical device company’s stock worth $304,000 after acquiring an additional 1,547 shares during the period. Pacer Advisors Inc. increased its holdings in shares of Globus Medical by 3.6% in the 1st quarter. Pacer Advisors Inc. now owns 34,365 shares of the medical device company’s stock worth $2,961,000 after acquiring an additional 1,188 shares during the period. Defilade Capital Management L.P. lifted its position in Globus Medical by 32.6% in the 1st quarter. Defilade Capital Management L.P. now owns 354,350 shares of the medical device company’s stock valued at $30,531,000 after purchasing an additional 87,138 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in Globus Medical by 20.0% in the 1st quarter. NewEdge Advisors LLC now owns 30,540 shares of the medical device company’s stock valued at $2,631,000 after purchasing an additional 5,091 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.